Entellus Medical Announces Release of MiniFESS(TM) Surgical Instruments and FocESS(TM) Sinuscopes
September 24 2015 - 4:08PM
Entellus Medical, Inc. ("Entellus Medical" or the "Company")
(NASDAQ:ENTL), a medical technology company focused on the design,
development and commercialization of products for the minimally
invasive treatment of chronic and recurrent sinusitis patients in
the physician office setting or operating room, today announced the
release of its MiniFESS family of products and its FocESS
Sinuscopes, representing a total of eleven new products. These
products are designed to enable, enhance and expand the number of
patients who can benefit from the superior patient experience and
improved healthcare economics offered by office-based treatment.
In combination with effective local anesthesia protocols, the
MiniFESS family of products features eight steel surgical
instruments designed to enable procedures from turbinate reductions
to anterior ethmoidectomies to be performed in the ENT physician
office instead of the operating room. This transition to the ENT
physician office offers patients reduced risk and requires less
time than a traditional operating room procedure using general
anesthesia.
The FocESS Sinuscope line features three scopes with 0-, 30-,
and 45-degree viewing angles. At 3 millimeters in diameter and 150
millimeters in length, and with a field of view that is as much as
30 millimeters greater than competing devices, the FocESS
Sinuscopes are designed to make office procedures even easier for
ENT physicians.
"We are committed to bringing technologies to the ENT market
that offer the opportunity to transform the patient and physician
experience," said Robert White, President and CEO of Entellus
Medical. "We believe that the MiniFESS and FocESS product lines,
along with our recently announced exclusive distribution of Fiagon
Image Guidance Technology, will continue to enable, enhance and
expand the number of patients that ENT physicians can treat in the
office using our technologies."
About Chronic Sinusitis and Balloon Sinus
Dilation:
Chronic sinusitis affects approximately 29 million American
adults, making it one of the most common health problems in the
United States. It is more prevalent than heart disease and asthma,
and has a negative impact on quality of life with chronic symptoms
and effects including facial pain and pressure, headaches, fatigue,
loss of smell, and sinus infections.
About Entellus Medical, Inc.
Entellus Medical is a medical technology company focused on the
design, development and commercialization of products for the
minimally invasive treatment of chronic and recurrent sinusitis
patients in the physician office setting or operating room. Its
XprESS family of products is used by ENT physicians to open
narrowed or obstructed sinus drainage pathways using balloon sinus
dilation. When used as a stand-alone therapy, Entellus Medical's
balloon sinus dilation products are the only devices proven in a
sufficiently powered prospective, multicenter, randomized,
controlled trial to be as effective as functional endoscopic sinus
surgery ("FESS"). Patients treated with Entellus Medical's products
in this trial in the ENT physician's office also experienced faster
recovery, less bleeding at discharge, less use of prescription pain
medication and fewer post-procedure debridements than patients
receiving FESS. In addition to its XprESS line of products,
Entellus Medical has recently introduced additional products
designed to aid in the diagnosis, treatment and post-operative care
of patients suffering from chronic sinusitis.
Entellus Medical currently markets its products in the United
States, Europe and Canada and sells its products through a direct
sales force in the United States and the United Kingdom. For more
information, please visit the Company's website at
www.entellusmedical.com.
Forward-Looking Statements:
All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are based on the current expectations of Entellus
Medical's management and involve known and unknown risks and
uncertainties that may cause Entellus Medical's actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements. Such risks and uncertainties
include, among others, adoption by ENT physicians of the Company's
MiniFESS family of products and FocESS Sinuscopes, the benefits the
Company expects to achieve as a result of the collaboration with
Fiagon and the integration of the Company's product portfolio and
the Fiagon IGS. Other factors that could cause actual results to
differ materially from those contemplated in this press release can
be found under the caption "Risk Factors" in the Company's Annual
Report on Form 10-K for the fiscal year ended December 31, 2014
filed with the Securities and Exchange Commission ("SEC"), and in
its other reports filed with the SEC. Entellus Medical undertakes
no obligation to update or revise any forward-looking statements,
even if subsequent events cause its views to change.
CONTACT: Leigh Salvo
415-513-1281
ir@entellusmedical.com
ENTELLUS MEDICAL INC (NASDAQ:ENTL)
Historical Stock Chart
From Jun 2024 to Jul 2024
ENTELLUS MEDICAL INC (NASDAQ:ENTL)
Historical Stock Chart
From Jul 2023 to Jul 2024